No Data
No Data
Express News | Biogen Inc : Piper Sandler Cuts Target Price to $313 From $335
Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $313
Piper Sandler analyst Christopher Raymond maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $335 to $313.According to TipRanks data, the analyst has a success rate of 51
Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts polled by Capital IQ.Price: 237.22, Change: +0.42, Percent Change: +0.18
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Morgan Stanley Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $311
Morgan Stanley analyst Terence Flynn maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $331 to $311.According to TipRanks data, the analyst has a success rate of 64.8%
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts by Capital IQ.Price: 231.00, Change: -1.75, Percent Change: -0.75